MA35932B1 - Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine - Google Patents

Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine

Info

Publication number
MA35932B1
MA35932B1 MA37338A MA37338A MA35932B1 MA 35932 B1 MA35932 B1 MA 35932B1 MA 37338 A MA37338 A MA 37338A MA 37338 A MA37338 A MA 37338A MA 35932 B1 MA35932 B1 MA 35932B1
Authority
MA
Morocco
Prior art keywords
activating enzyme
chemical entities
ubiquitin activating
pyrazolopyrimidinyl
inhibitors
Prior art date
Application number
MA37338A
Other languages
English (en)
Inventor
Paul E Fleming
Jeffrey L Gaulin
Roushan Afroze
Indu Bharathan
Jeffrey P Ciavarri
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingchun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA35932B1 publication Critical patent/MA35932B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des entités chimiques inhibiteurs de l'enzyme d'activation de l'ubiquitine (uae), dont chacune est un composé de formule (i), ou un sel pharmaceutiquement acceptable de celles-ci, dans laquelle y est formule (2) et w, z, xy, ry1, ry2 et ry3 sont tels que définis dans la description; des compositions pharmaceutiques comportant les entités chimiques; et des procédés d'utilisation des entités chimiques. Ces entités chimiques sont utiles pour le traitement de troubles, en particulier des troubles de prolifération cellulaire, y compris des cancers.
MA37338A 2012-02-17 2014-09-10 Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine MA35932B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
PCT/US2013/026113 WO2013123169A1 (fr) 2012-02-17 2013-02-14 Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine

Publications (1)

Publication Number Publication Date
MA35932B1 true MA35932B1 (fr) 2014-12-01

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37338A MA35932B1 (fr) 2012-02-17 2014-09-10 Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine

Country Status (30)

Country Link
US (4) US9290500B2 (fr)
EP (3) EP3536692B1 (fr)
JP (1) JP6122877B2 (fr)
KR (1) KR20140123104A (fr)
CN (1) CN104136399B (fr)
AR (1) AR092797A1 (fr)
BR (1) BR112014020365B1 (fr)
CA (1) CA2864672C (fr)
CL (1) CL2014002181A1 (fr)
CO (1) CO7071135A2 (fr)
CR (1) CR20140380A (fr)
DO (1) DOP2014000187A (fr)
EA (1) EA035020B1 (fr)
EC (1) ECSP14019113A (fr)
ES (1) ES2739150T3 (fr)
GE (1) GEP201706687B (fr)
HK (1) HK1201817A1 (fr)
IL (1) IL234016A0 (fr)
MA (1) MA35932B1 (fr)
MX (1) MX352963B (fr)
NZ (1) NZ628969A (fr)
PE (1) PE20142244A1 (fr)
PH (1) PH12014501832A1 (fr)
SG (2) SG10201606581RA (fr)
TN (1) TN2014000351A1 (fr)
TW (1) TWI593688B (fr)
UA (1) UA116534C2 (fr)
UY (1) UY34629A (fr)
WO (1) WO2013123169A1 (fr)
ZA (1) ZA201406103B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｕｂａ６のインドール置換ピロロピリミジニル阻害剤
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
TW201628621A (zh) 2014-10-29 2016-08-16 千禧製藥公司 泛素活化酶抑制劑及輻射之施用
US20180133221A1 (en) * 2014-10-29 2018-05-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (fr) * 2021-08-16 2023-02-23 Moya Bio Ltd. Analogues de nucléosides à base d'azole et de furane fusionnés et leurs utilisations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524662A (ja) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ES2285164T3 (es) 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (fr) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제
WO2007099021A1 (fr) * 2006-02-28 2007-09-07 Sez Ag Dispositif et procede pour traitement liquide d'articles en forme de disque
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
WO2009042013A1 (fr) 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Procédé pour la synthèse d'inhibiteurs de l'enzyme d'activation e1
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (fr) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines pour traitement de la myopathie de duchenne
WO2010088518A2 (fr) 2009-01-31 2010-08-05 Kalypsys, Inc. Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
SG11201400102WA (en) 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｕｂａ６のインドール置換ピロロピリミジニル阻害剤
CN105492429A (zh) 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso

Also Published As

Publication number Publication date
US9290500B2 (en) 2016-03-22
US20170217968A1 (en) 2017-08-03
SG10201606581RA (en) 2016-09-29
US20130217682A1 (en) 2013-08-22
KR20140123104A (ko) 2014-10-21
IL234016A0 (en) 2014-09-30
SG11201404757WA (en) 2014-09-26
GEP201706687B (en) 2017-06-26
HK1201817A1 (en) 2015-09-11
ECSP14019113A (es) 2015-09-30
WO2013123169A1 (fr) 2013-08-22
US9796725B2 (en) 2017-10-24
PE20142244A1 (es) 2015-01-07
EP2814791A4 (fr) 2015-08-19
US20160244455A1 (en) 2016-08-25
TW201345909A (zh) 2013-11-16
BR112014020365B1 (pt) 2023-02-23
EA201400831A1 (ru) 2014-12-30
AR092797A1 (es) 2015-05-06
ZA201406103B (en) 2017-11-29
CA2864672C (fr) 2018-01-09
MX2014009944A (es) 2014-11-10
PH12014501832A1 (en) 2014-11-17
US20170369499A1 (en) 2017-12-28
US10202389B2 (en) 2019-02-12
CR20140380A (es) 2014-10-28
TWI593688B (zh) 2017-08-01
ES2739150T3 (es) 2020-01-29
EP2814791A1 (fr) 2014-12-24
EP3173413A1 (fr) 2017-05-31
MX352963B (es) 2017-12-15
UY34629A (es) 2013-09-02
EP3536692A1 (fr) 2019-09-11
EP3173413B1 (fr) 2019-05-01
JP6122877B2 (ja) 2017-04-26
CN104136399B (zh) 2018-08-07
DOP2014000187A (es) 2014-10-15
NZ628969A (en) 2017-03-31
CL2014002181A1 (es) 2014-12-12
TN2014000351A1 (en) 2015-12-21
CO7071135A2 (es) 2014-09-30
BR112014020365A2 (pt) 2020-12-22
CA2864672A1 (fr) 2013-08-22
CN104136399A (zh) 2014-11-05
US20140088096A9 (en) 2014-03-27
EP3536692B1 (fr) 2021-04-07
EA035020B1 (ru) 2020-04-17
UA116534C2 (uk) 2018-04-10
JP2015508775A (ja) 2015-03-23
US9663525B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
MA35932B1 (fr) Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA33032B1 (fr) Pyrimidines condensees
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201201665A1 (ru) Новые соединения
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
UA107100C2 (xx) Конденсовані гетероароматичні піролідинони як інгібітори syk
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
MA32997B1 (fr) Macrolide anti-inflammatoire
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MA35814B1 (fr) Thiazoles à substitution 2-(chroman-6-yloxy) et leur utilisation comme produits pharmaceutiques
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes
MA38206B1 (fr) Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées
MA38207A2 (fr) Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées